Molecular Partners AG fell 11.2% on Tuesday, November 3, 2026, on 2,400 shares. No headline about MOLN came out that day or the day before in the news feeds we follow, so the move may come from news we don't track, the sector or trading alone.
Molecular Partners AG (MOLN:NASDAQ) closed at $3.09 on November 9, 2026, down 3.89% on the day. It is trading at its 52-week low of $3.09. Over the past year, it lost 23.3%. Molecular Partners AG is part of the Health Care sector.
In 252 trading sessions since November 7, 2025, MOLN closed higher on 102 days (40%). Its best day was June 12, 2026 (+10.78%) and its worst was November 3, 2026 (-11.21%). The stock moved 10% or more in a single session 5 times. It opened at least 5% above the previous day's high 5 times.
Molecular Partners AG is a clinical-stage biopharmaceutical company. The company focuses on the discovery, development and prospective commercialization of a new class of biopharmaceutical products. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.
Find more stocks like MOLN with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.